| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T145 |
0-258 |
Sentence |
denotes |
In particular, tenofovir disoproxil (Viread; 2001) is an adenine-based acyclic nucleotide analog (Figure S1) that, following activation, acts as a competitive inhibitor of reverse transcriptase, and subsequently, it leads to DNA chain elongation termination. |
| T146 |
259-583 |
Sentence |
denotes |
Activation of the drug starts with the hydrolysis of the external esters followed by spontaneous release of carbon dioxide and formaldehyde to form the corresponding tenofovir, a nucleoside monophosphate, which subsequently undergoes two phosphorylation steps to form tenofovir diphosphate, the active drug (Figure S1) [64]. |
| T147 |
584-625 |
Sentence |
denotes |
It was first approved in 2001 by the U.S. |
| T148 |
626-712 |
Sentence |
denotes |
FDA and is prescribed for the oral treatment of HIV-1 and chronic HBV infections [65]. |
| T149 |
713-896 |
Sentence |
denotes |
It is also available in many other combinations with emtricitabine, lamivudine (Cimduo; 2018), doravirine and lamivudine (Delstrigo; 2018), and efavirenz and lamivudine (Symfi; 2018). |
| T150 |
897-1175 |
Sentence |
denotes |
The efficacy of emtricitabine and tenofovir disoproxil as a prophylactic combination against SARS-CoV-2 infection is being evaluated in a large randomized, double-blind, controlled with placebo clinical trial for health care providers exposed to COVID-19 patients (NCT04334928). |
| T151 |
1176-1348 |
Sentence |
denotes |
The two drugs have been reported by a recent computational work as potential inhibitors of RdRp of SARS-CoV-2 [55,66], yet this potential is to be experimentally confirmed. |
